First‐generation <i>EGFR</i> tyrosine kinase inhibitor therapy in 106 patients with compound <i>EGFR</i> ‐mutated lung cancer: a single institution's clinical practice experience

Abstract

There was significant heterogeneity among the compound EGFR mutations and their response to first-generation TKIs. Individualized treatment in clinical practice should be considered for each case.